Who We Are

Leaders in Targeted C3 Therapies

At Apellis, we are experts in complement and leaders in targeted C3 therapies. By controlling complement, part of the body’s immune system, we aim to develop transformative therapies for people living with a broad range of serious diseases across hematology, ophthalmology, nephrology, and neurology.

Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Pegcetacoplan, our investigational targeted C3 therapy, has broad platform potential to treat many diseases where patients have few or no treatment options available.

The Pursuit of Groundbreaking Science

Founded in 2009 by a small group of entrepreneurs, including a physician-scientist who is our CEO, Apellis was established with the ambition to become the first company to develop a targeted C3 therapy for serious diseases driven by complement. Controlling C3 was viewed as scientifically difficult, even impossible, but our founders recognized the significant unmet needs of patients living with complement-driven diseases.

More than 10 years later, the concept of targeting C3 has been validated with positive Phase 3 data in paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. Pegcetacoplan also has the potential to become the first treatment for geographic atrophy, a leading cause of blindness around the world, and to elevate the standard of care for several serious rare diseases. We believe we are just scratching the surface of the potential of C3.

Bold at Our Core

Our company is formed by people who care, are fearless in the face of a challenge, love the work they do, are resourceful, and continually pursue the highest level of scientific integrity. These values guide every decision that we make as we work toward our vision of being a compassionate organization known for its revolutionary science and contributions to humankind.